he certainly came but young blood need the health minister in prague has said he will wait for the e.m.a.'s approval before allowing sputnik v. to be used in check as long as i'm the health minister i will insist that vaccination in the czech republic is not done with the drug there's not been approved by the european medicines agency but if he was to change his mind there are plenty within the government who would be very keen to see the russian vaccine rolled out across the country i would not seek to devalue the results of russian science just because it comes from russia we have a situation where there are not enough vaccine supplies in europe so the e.u. should have negotiated with other manufacturers including manufacturers from russia a long time ago. well elsewhere with one of the major vaccines that's being used here in europe the astra zeneca job italy and denmark could become the latest e.u. member states to suspend its use they joined by e.u. member states in europe norway and iceland in carrying out this suspension in denmark it follows the death of one person with a blood c

the european drug regulated the e.m.a.stra shot outweighs the risks its executive spoke about this issue a little earlier on. >> we are convince that the astra vaccine in preventing covid-19 with its associated risks of hospitalization deaths outweighs the risk of these side effects. alix: joining us now is scott rosenstein. global health special advisor joins us. the real question is can europe get away from astrazeneca? how do they come back from all this doubt and bad press it's had? >> i think the astrazeneca vaccine makes up a large part of the strategy particularly in the short term. and even just the perception of safety issues is going to possibly drive down uptake and that vaccine possibly and even other vaccines, and that puts more pressure on a number of the e.u. countries that are struggling with the logistics of the rollout. many of them are struggling with the third wave or a potential third wave in a surge of cases it's going to be a real challenge in this short term as the e.u. countries build up the capaci

this is probably the kind of thing e.m.a. whether the incidents rate is quite normal of course if it has anything to do with the vaccine and if other vaccines in the same conditions are pretty much reporting the same rates. i would suspect that if the numbers of those once are very likely to be lifted by thursday. anna: thanks very much, eric. thank you for your perspective. it's an interesting conversation. coming up, following the dots. bloomberg economic say a few might drift higher but the committee will hold the line. i'm talking of course about the fed's plot. we look ahead to the fed conversation this week. this is bloomberg. ♪ anna: welcome back to the european market open. 53 minutes in the trading session and european equity markets moving up around .34%. it's fed week where our attention lies and let's look at the markets with laura for macrostrategies. it is fed week and are we seeing calm before the storm, is it of comfort or concern? laura: i'm not quite sure whether it is comfort or concern because markets don'

possibility that the vaccine is it associated with these effects as far as i can i can tell some of the the e.m.a's already looked at this in relation to austria and it's had no no specific links with the vaccine because i've done that study comparing blood clots and other and other effects in the general health healthy populations and i say the normal population versus the banks and to population so you have to look at least things very very carefully is there not a problem with. globetrotting in other countries as well or is this just a one off for example in denmark that's a really important thing to to find out and really anybody with the sort of oversight multi-national oversight like the air may do that the european metal medicines agency has to take the sort of questions and concerns of each member state into account when it when it gives gives or thora t. i don't think that one can say the a.m.a. is being slipshod or careless you know there there are questions that there are still be slightly different from regulators in the u.k. or in other countries so overall one gets quite a broad pic

was in there in the run up to the e.m.a.'s announcement please take us through it. yes that's right many people wondering what the decision would be by the e m a we know it's now a new approval for the astra zeneca vaccine which is considered by the e m a to be safe and effective with the benefits outweigh the risks associated with it and saying in that press conference today that it's not associated with the overall risk of blood clots however they could not definitively rule out that they would be a link and so there will be further investigations this is what the director had to say after days of in-depth analysis of lab results clinical reports autopsy reports and further information from the clinical trials we still cannot. definitively link between these cases and the taxi there are also still some uncertainties we have seen some very rare case people it's describing specific unusual events of communication of this and trying to pin you know and bleeding so we'll continue to gather more information on these conditions including additional studies and we'll kee

zeneca vaccine was a precautionary measure until further information was provided in particular by the e.m.a.'s so now that we do have that information from the may it is expected that german authorities will realize how the use of the astra zeneca vaccine we're actually expecting the german health minister to talk to the press any minute now about whether germany will reauthorize the use of the astra zeneca vaccine and it's important to stress leyla that if germany does reauthorize the use of the astra zeneca vaccine that would certainly help germany in its already very slow coronavirus vaccine rollout germany actually counts on the astra zeneca vaccine to not only speed up its vaccination program but also to fulfill that very important promise that has been reiterated by chancellor angela merkel in various occasions that every german adult will receive an offer of under coronavirus vaccine until the end of the summer so in around 6 months so this is asian is particularly important for germany in order for authorities to be able to fulfill that promise that they have made to all of old germ

possibility that the vaccine music associated with these effects as far as i i can tell some of the the e.m.a.'s already looked at this in relation to austria and as for no no specific links with the vaccine because i've done that study comparing blood clots and other and other effects in the general health healthy population should i say the normal population versus the vaccinated population so you have to look at the scenes very very carefully there's a bit of big issue hasn't there about confidence in vaccines generally and there's been there's been the big issue with the in europe about the effect of age on the effectiveness of vaccines. and of course as i say you have to investigate every serious side effect carefully but there is a big commercial dimension to all of this as well. money down the drain that's how the huge temporary covert hospitals are being described after wards revealed that most are now being closed down having treated hardly any patients and has led to questions over the government's handling of the pandemic as partridge reports. 4 of england's nightingale hospitals a

the astra zeneca vaccine these are all the bizarre decision actually when europe's own regulator the e.m.a.'s systems that the vaccine is safe and where all the data that we have so far across the u.k. and europe suggests that the right old blood clot development index in 1000 individuals is no different from the vaccinated general population so i think it's a worry to pulls vaccination particularly at a time when infections rampaging through europe what what what what what could justify a decision like this then i mean obviously it sounds like that these health ministers in these countries that they know something that the rest of the of us do not. do you agree i mean can is that plausible. well that is a possibility and of course where you do see any adverse side effects it's important they're investigated of course everything to do with that sainz a medicine is about balancing risks and kovi itself as a disease is much worse than any of the side effects reported to any of these vaccines some people had said that maybe there is actually no science behind this decision and maybe it was ju

developed clots the e.m.a.'s says the benefits of the shot outweigh the risk but it will continue to investigate reports of rare clotting disorders based on the evidence available and after days of in-depth analysis of lab results clinical reports autopsy reports and present information from the clinical trials we still cannot rule out definitively and link between these cases and the taxi well all eyes today were on amsterdam where the a.m.a. the european medicines agency is headquarters our correspondent baird richard he's been following the story for us good evening to you barents the a.m.a. has spoken i'm wondering though is this the final word can inoculations with the astra zeneca vaccine can they restart. the european medicines agency can only recommend to restart the vaccination the decision has to be taken by the national authorities in every single member state of the european union and around the world and actually the intercalation of a stopped actually because of the 60 plus customer services and it

possibility that the vaccine is it associated with these effects as far as i can i can tell some of the the e.m.a.'s already looked at this in relation to austria and it's had no no specific links with the vaccine because i've done that study comparing blood clots and other and other effects in the general health healthy populations and i say the normal population versus the banks and the population so you have to look at least things very very carefully is a been a big issue hasn't there about confidence in vaccines generally and there's been there's been the big issue with the in europe about the fact of age on the effectiveness of vaccines. and of course as a you have to investigate every serious side effect carefully but there is a big into the commercial dimension to all of this as well you need to look at for the number of people who are in your report said that batch of fact see they've gone to. i said probably many different countries is there a problem with. globetrotting in other countries as well or is this just a one off for example that you can bear markets a really important thing t

to one person for every 170000 people given the vaccine and on that basis on the 11th of march the e.m.a.'s ruling was that it was still better to administer the vaccine the not to administer the vaccine we were hoping that perhaps we would hear slightly more detail from the w.h.o. regarding specifically this central idea about the relative safety of the vaccine but seeing is the news conference had only started in the course of the last 10 minutes or so 5 to 10 minutes or so perhaps that they will come back to this particular issue as the meeting unfolds dominick. what do you think all of this is going to do. the public trust in the vaccine because now we have a few countries in the european union who are suspending use of this vaccine but this axiom is all being used widely in the u.k. as it. yes it's worth remembering that on the one hand you have countries such as the u.k. who have almost been pioneering the use of the astra zeneca vaccine really sealing a march on other countries by giving it to many millions of people in their general population the people who they felt need to hav

to chart a different skin porous charlotte this weight was in there for many in the run up to the e.m.a.'s and months meant take us through it. that's why the e.m.e.a. confirming on thursday that they can say that mr zeneca to be a safe effective vaccine when it comes to mitigating the effects of 19 saying that this is a vaccine where the benefits continue to outweigh any associated risks but also confirming that this vaccine is not associated with the overall risk of blood clots however because of the blood clotting that has been seen in some patients a handful of patients across the european union there will not be warnings added to this job warnings for those who take it that if they spot certain signs how to mitigate them and of course more information being the health care providers who or ministering this job this is what the director had to say. after days of in-depth analysis of large screen nicol reports autopsy reports and further information from the clinical trials we still cannot. definitively link between these cases and the taxi there are also still some uncertainty we ha

possibility that the vaccine is it associated with these effects as far as i i can tell some of the the e.m.a.'s already looked at this in relation to austria and it's right no no specific links with the vaccine because i've done that study comparing blood clots and other and other effects in the general health healthy populations let's say the normal population versus the vaccinated population so you have to look at these things very very carefully after seneca has said that its job is absolutely safe and should go forward of course there might be potentially a bit of competition between pfizer and modernity but do you think you think there could be some who may have perhaps a lack of faith in astra zeneca after hearing these reports of adverse side effects i think so and i think there's a been a big issue hasn't there about confidence in vaccines generally and there's been there's been the big issue with the new europe about the effect of age on the on on the on the effectiveness of vaccines. and of course as i say you have to investigate every serious side effect carefully but there is a b

it's a strange one or project and courage governments to follow science follow the science and the e.m.a.'s problem science of the show and they said keep it in this vaccine while we look at these cases and then with the m i might well say there is a risk you say and then let's see what i say next you know well i you suggested the f.e.m.a. and have them follow the science but. if we look at the at the back to have to prove so far. they haven't proved the the russian or the chinese back then despite the fact that they scientifically have a pretty strong efficacy and do you think this slow process of starting to pick a shadow of these boring vaccines has anything to do with politics if it might mean that more to approving a vaccine in the published data they've got to go and visit the factory that makes is they're going to sign off on the production process you know and that would be in china or russia or anywhere maybe they haven't done that maybe they're doing about how the guy was a machine without one you got to check several boxes remember before vaccines approved and includes product

that the european medicines agency spokeswoman there was putting across the point of view that the e.m.a.'s been putting across for some time that in its estimation the astra zeneca vaccines the benefit of using the vaccine far outweighs the potential risks that are associated with having it administered it's worth making the point that the ratio of blood clots to patients based on the analysis and the data that the inmate was putting out just a few days ago was one in a $170000.00 now that would clearly suggest. the reason why the e.m.e.a. is sticking to this line that it believes that that the danger that the risk that may be associated with this particular vaccine well is the benefits far outweigh it but clearly again no definitive final perspective from there she wants to wait until thursday because we know that on thursday the evaluation will be complete and that we will get to hear what the evaluation is very much rides on what that of that final evaluation will be so many countries have a stake in the astra zeneca vaccine at least in the uptake of it so many countries have built t

the e.m.a. is investigating the incidents but advises that in the meantime vaccines can continue to be used. cyril vanier, cnn, london. >>> and italy is imposing new restrictions starting monday as covid cases there continue to rise. and the entire country will actually be considered a red zone and will be under lockdown during the upcoming easter weekend. here's delia gallagher with more on that. delia. >> reporter: italians are preparing once again to head into lockdown starting on monday. half of italy's 20 regions including cities like rome, milan, and venice will be on full lockdown. easter weekend will ee see a national lockdown. although italy's hospitals are still able to manage, we are not in an emergency situation. they are seeing their daily case numbers rise. the latest case count was just under 26,000 cases daily. that is a record since november. and they are particularly concerned about the presence of variants which increase the rate of transmission. so the prime minister, mario d

countries have paused inoculations with the vaccine after a few cases of blood clots earlier this week the e.m.a.'s said there is no indication the vaccine caused the clotting meanwhile germany france and italy say they will follow the agency's guidance on the way forward. well all eyes are on absent and where the e m a is headquartered correspondent barratry guard is on the story for you get to see a bear and the european mrs agency said announce its findings momentarily we're expecting it to be actually right now that has been this phone do we know the reason. the deliberations are still going on the experts on this security committee from the 27 member states and other experts in amsterdam on a big huge video because as that can take some time as far as we know it is not an indication that it is difficult or the delay is not due to any conflict in the agency because it's vitally expected that the a visit prove the u.s. or the senate vaccine once again and say there is no evidence that these blood clots for a caused by the vaccine in the in a night or that these side effects also. not unusual